Status:
COMPLETED
Ab Interno Gelatin Stent With Mitomycin C Using Targeted Supra-tenon's Placement
Lead Sponsor:
Prism Eye Institute
Collaborating Sponsors:
Allergan
Conditions:
Glaucoma
Eligibility:
All Genders
30-90 years
Brief Summary
The Xen-45 gelatin microstent is a novel, bleb-forming microinvasive glaucoma surgery (MIGS). Despite demonstrating similar efficacy and safety to trabeculectomy (traditional surgery), the Xen-45 gela...
Detailed Description
The Xen-45 gelatin microstent (Allergan, Dublin, Ireland) is a novel, bleb-forming microinvasive glaucoma surgery (MIGS). Creation of a filtering bleb through the gel stent and under the conjunctiva l...
Eligibility Criteria
Inclusion
- Patients aged 30-90 with primary or pigmentary/pseudoexfolliative open angle, primary closed angle, or combined mechanism glaucoma with IOP of 18-40 mmHg on maximum tolerated medical therapy who received a gelatin stent with MMC at Prism Eye Institute from June 2012 to August 2019.
Exclusion
- Other forms of glaucoma
- Prior incisional glaucoma surgery
- CPC
- Prior corneal graft (PKP, DALK, DSAEK, DMEK).
Key Trial Info
Start Date :
June 25 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 20 2020
Estimated Enrollment :
142 Patients enrolled
Trial Details
Trial ID
NCT04454138
Start Date
June 25 2019
End Date
April 20 2020
Last Update
August 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prism Eye Institute
Oakville, Ontario, Canada, L6H 0J8